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INTRODUCTION
Experimental evidence indicates an important role of cyclic
guanosine monophosphate (cGMP) in antinociceptive action
(1, 2). This evidence is in line with the observation that intra-
plantar injection of dibutyryl-cGMP produced antinocicep-
tion in inflammatory hyperalgesia rats (3). Moreover, intrathe-
cal 8-bromo-cGMP reduced mechanical allodynia in neuro-
pathic rats (4). Therefore, cGMP seems to be very critical
for the regulation of the nociceptive transmission. Guanylyl
cyclase catalyzes the formation of cGMP from GTP, leading
to the synthesis of cGMP, whereas cGMP-specific phospho-
diesterase catalyzes the hydrolysis of cGMP to GMP, there-
by ending signal transduction (5). Accordingly, intracellular
cGMP concentrations are regulated by the action of guany-
lyl cyclase and the rate of degradation by cGMP-specific
phosphodiesterase (5, 6).
Sildenafil (Viagra
�) is a novel inhibitor of cGMP-specific
phosphodiesterase 5, which has been shown to be effective
in the treatment of male erectile dysfunction (7, 8). Recent-
ly, it has been reported that intrathecal sildenafil produced
an antinociception, which is mediated through the nitric
oxide (NO)-cGMP pathway (9, 10). It is demonstrated that
morphine reversed not only acute nociception but also tis-
sue injury hyperalgesia through the action on spinal opioid
receptor (11-14). Furthermore, several lines of evidence sug-
gest that opioid-induced antinociception may be related to
the activation of the NO-cGMP pathway (15-17). These
observations, conversely, may lead to a hypothesis that the
effect of the cGMP-specific phosphodiesterase inhibitor may
be affected by the opioid system. Therefore, understanding
the functional role of cGMP and opioid receptor in altered
nociception may help provide novel targets for pain therapy. 
The purpose of the present study was to evaluate the char-
acteristics of pharmacological interaction between spinal
sildenafil and morphine in the formalin test which shows
tissue injury pain leading to the facilitated state as well as
acute pain (11). We further clarified the possibility of con-
tribution of spinal opioid receptor on the action of sildenafil.
MATERIALS AND METHODS
Animal handling and experimental procedures were app-
roved by the Institutional Animal Care Committee of Research
Institute of Medical Science in Chonnam National Univer-
sity. Adult male Sprague-Dawley rats weighing 250-300 g
were used in all experiments. The animals were housed in
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Additive Antinociception between Intrathecal Sildenafil and Morphine
in the Rat Formalin Test
The possible characteristics of spinal interaction between sildenafil (phosphodi-
esterase 5 inhibitor) and morphine on formalin-induced nociception in rats was exam-
ined. Then the role of the opioid receptor in the effect of sildenafil was further inves-
tigated. Catheters were inserted into the intrathecal space of male Sprague-Daw-
ley rats. For induction of pain, 50 μ L of 5% formalin solution was applied to the hind-
paw. Isobolographic analysis was used for the evaluation of drug interaction between
sildenafil and morphine. Furthermore, naloxone was intrathecally given to verify
the involvement of the opioid receptor in the antinociception of sildenafil. Both silde-
nafil and morphine produced an antinociceptive effect during phase 1 and phase 2
in the formalin test. The isobolographic analysis revealed an additive interaction
after intrathecal delivery of the sildenafil-morphine mixture in both phases. Intrathe-
cal naloxone reversed the antinociception of sildenafil in both phases. These results
suggest that sildenafil, morphine, and the mixture of the two drugs are effective
against acute pain and facilitated pain state at the spinal level. Thus, the spinal
combination of sildenafil with morphine may be useful in the management of the
same state. Furthermore, the opioid receptor is contributable to the antinocieptive
mechanism of sildenafil at the spinal level.
Key Words : Antinociception; Drug Interactions; Injections, Spinal; Phosphodiesterase 5 Inhibitor; Sildenafil;
Morphine; Receptors, Opioid
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Accepted : 19 February 2008groups of four, with free access to standard rat diet and tap
water in a room under 12:12 hr light/dark cycle. For the pur-
pose of drug administration, an intrathecal catheter was im-
planted under enflurane anesthesia and aseptic surgical con-
ditions as described previously (18). A polyethylene-10 tube
was inserted into the subarachnoid space through a slit made
in the atlantooccipital membrane. The catheter was advanced
caudally 8.5 cm to reach the level of the lumbar enlargement.
The external end of the catheter was tunneled subcutaneous-
ly, exiting at the top of the head and plugged with a piece of
steel wire. The skin was closed using 3-0 silk sutures. After
catheter implantation, rats were housed in individual cages.
All animals with a neurological deficit postoperatively were
rejected from further study and killed immediately with an
overdose of volatile anesthetics. At least 5 days of postsurgi-
cal recovery were allowed before the behavioral study.
The following drugs were used in this study: sildenafil
and morphine sulfate (Sigma Chemical Co., St. Louis, MO,
U.S.A.), naloxone hydrochloride (Sigma). Sildenafil was kindly
provided by Korea Pfizer. Sildenafil was dissolved in dimethyl-
sulfoxide (DMSO), and morphine and naloxone were dis-
solved in normal saline. Intrathecal administration of these
agents was performed using a hand-driven, gear-operated
syringe pump. All drugs were delivered in a volume of 10 μ L
solution, followed by an additional 10 μ L of normal saline
to flush the catheter. 
The formalin test was done as a nociceptive test. The ani-
mals were injected subcutaneously with 50 μ L of 5% for-
malin solution into the plantar surface of the hind paw using
a 30-gauge needle. The formalin injection produced specific
pain behavior characterized as rapid and brief withdrawal or
flexing of the injected paw. This behavior was called a ‘‘flinch-
ing response’’. Such pain behavior was therefore quantified
by periodically counting the incident of flinching of the inject-
ed paw. The number of flinches was counted for 1-min peri-
od at 1 and 5 min and at 5-min intervals from 10 to 60 min.
Formalin-induced flinches were observed in a characteristic
biphasic response. The initial phase 1 (0-9 min) was followed
by a relatively short quiescent period, which was then fol-
lowed by a late phase 2 (10-60 min). At the end of the exper-
iment, the rats were killed with volatile anesthetics.
On the day of experiments, the rats were placed in a restraint
cylinder and allowed to adapt for 15-20 min. Rats were then
placed into one of the experimental groups. The control study
was done with intrathecal DMSO or saline. Animals were
tested only once in the formalin test. The total number of
rats used was 113 with 5-7 rats per group. The researcher
was blind to the drug given to experimental animals.
For evaluation of the dose-response of the antinociceptive
action of sildenafil (1, 3, 10, and 30 μ g) and morphine (1, 3,
10, and 30 μ g), experimental rats received two drugs intrathe-
cally. Intrathecal drugs were injected 10 min before formalin
injection. Each ED50 value (an effective dose producing a 50%
reduction in control formalin response) for the agents was
calculated separately in two phases. 
The isobolographic analysis (19) was used to determine
the nature of pharmacologic interaction between sildenafil
and morphine in the formalin test. This method was based
on the comparison of doses determined to be equieffective.
At first, each ED50 value was determined from the dose-res-
ponse curves of agents alone. Next, sildenafil and morphine
were intrathecally coadministered at a dose calculated using
the ED50 values and fractions (1/2, 1/4, and 1/8) of ED50 for
each drug. The ED50 values of the mixture were calculated
from the dose-response curves of the combined drugs, and
the combinations were used to plot the isobologram. In this
experiment, the isobolograms were used to express the effect
of the sildenafil-morphine combinations. An isobologram
was constructed by plotting the ED50 values of the single
agents on the X and Y axes, respectively. The theoretical
additive dose combination was then calculated. From the
variance of the total dose, individual variances for the agents
in the combination were obtained. Furthermore, to describe
the magnitude of the interaction, a total fraction value was
calculated. 
Total fraction value =
ED50 of drug 1 combined with drug 2  
+
ED50 for drug 1 given alone
ED50 of drug 2 combined with drug 1
ED50 for drug 2 given alone
The fraction values indicate what portion of the single ED50
value was accounted for by the corresponding ED50 value for
the combination. Values near 1 indicate an additive interac-
tion, values greater than 1 imply an antagonistic interaction
and values less than 1 indicate a synergistic interaction. The
mixture was delivered intrathecally 10 min before the for-
malin test.
To determine whether the effect of intrathecal sildenafil
was mediated through opioid receptor, opioid receptor antag-
onist (naloxone 0.3 μ g) was intrathecally administered 10
min before the delivery of sildenafil (30 μ g). The maximum
dose of naloxone used was chosen based on pilot experiments
and the previous study (20) and this dose was ineffective at
ameliorating the control formalin response. The formalin
test was done 10 min after administration of sildenafil. The
experiment was conducted in phase 1 and phase 2, respec-
tively. 
In order to evaluate the behavioral changes of sildenafil
and morphine, additional rats (n=10) received the highest
doses of agents used, and were examined 5, 10, 20, 30, 40,
50, and 60 min after intrathecal administration. Motor func-
tions were assessed by examining the righting and placing/
stepping reflexes. The former was evaluated by placing the
rat horizontally with its back on the table, which normally
gives rise to an immediate coordinated twisting of the body
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the dorsum of either hind paw across the edge of the table.
Normally, rats try to put their paws forward into a position
for walking. Changes in motor functions were scored as: 0,
normal; 1, slightly deficient; 2, moderately deficient; and 3,
severely deficient. 
Data were expressed as mean±SEM. In the formalin test,
the time response data or the dose-response data were presented
as the number of flinches or as percentage of control in each
phase. To calculate the ED50 values for each drug, the num-
ber of flinches was converted to a percentage of control: %
of control=([sum of phase 1or 2 flinching count with
drug]/[sum of control phase 1or 2 flinching count])×100.
Dose-response data were analyzed by one-way analysis of
variance with Bonferroni for post hoc. The dose-response lines
were fitted using least-squares linear regression and ED50
and its 95% confidence intervals were calculated according to
the method as described previously (21). The difference bet-
ween theoretical ED50 and experimental ED50 was analyzed
by t-test, with p<0.05 being considered statistically signifi-
cant.
RESULTS
The pharmacological treatments employed with sildenafil
and morphine did not produce any motor impairment in
experimental rats as revealed by the righting and placing/
stepping reflexes. 
In control groups, the sum of the number of flinches did
not differ from each other in both phases (saline:DMSO; 21
±2:19±1 in phase 1, 159±10:159±13 in phase 2). 
Fig. 1 displays the time course of intrathecal sildenafil and
morphine, administered 10 min before formalin injection.
Intrathecal sildenafil and morphine resulted in the dose-
dependent inhibition of the flinching response during phase
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Fig. 1. Time effect curve of intrathecal sildenafil (A) and morphine (B) for flinching in the formalin test. Each drug was administered 10 min
prior to the formalin injection. Formalin was injected subcutaneously at time 0. Data are presented as the number of flinches. Each line
represents mean±SEM of 6-7 rats. 
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Fig. 2. Dose-response curve of intrathecal sildenafil and morphine for flinching in the formalin test. Data are presented as the percentage
of control in phase 1 (A) and phase 2 (B). Sildenafil and morphine dose-dependently inhibited the flinches in both phases. Each line rep-
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Dose (μ g) B1 and phase 2 in the formalin test (Fig. 2). The phase 1 ED50
values (95% confidence intervals) of sildenafil and morphine
were 19.1 (6.3-58.2) and 10.6 μ g (3.9-29.3 μ g), respectively.
The ED50 values (95% confidence intervals) of sildenafil and
morphine for phase 2 were 12.3 (6.9-21.5) and 3.3 μ g (1.8-
6.1 μ g), respectively. 
Isobolographic analysis revealed an additive interaction
between intrathecal sildenafil and morphine during phase 1
and 2 in the formalin test (Fig. 3). The experimental ED50
value was significantly lower than the theoretical ED50 value.
Accordingly, the ED50 values (95% confidence intervals) of
sildenafil in the mixture of sildenafil and morphine for phase
1 and phase 2 were 13.6 (4.7-38.9) and 7.6 μ g (3.8-15.3 μ g),
respectively. Each total fraction value for the mixture of silde-
nafil and morphine in phase 1 and phase 2 were 0.91 and
0.98, indicating an additive interaction.
The antinociceptive effect of sildenafil was reversed by int-
rathecal naloxone (Fig. 4B, C).
DISCUSSION
Formalin-induced nociception consists of two different
nociceptive states, acute nociception (phase 1) followed by
the facilitated state (phase 2). The phase 1 response appears
to result from the immediate and intense increase in the pri-
mary afferent activity. On the other hand, the phase 2 response
mirrors the activation of a wide dynamic range of dorsal horn
neurons with a very low level of ongoing activity in the pri-
mary afferent. Therefore, phase 2 reflects a facilitated state
which appears to be a prominent and intensified pain state
in spite of a reduced level of afferent input (22). This pain
model may serve as a tool for observing the effects of various
analgesic agents on these two pain types at once. 
In the present study, intrathecal sildenafil suppressed the
flinching response during phase 1 and phase 2 in the forma-
lin test. These findings suggest that sildenafil may be active
against acute pain and the facilitated state at the spinal level,
which is consistent with the previous observation (9). Anoth-
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Fig. 3. Isobologram for the interaction between intrathecal sildenafil and morphine during phase 1 (A) and phase 2 (B) in the formalin test.
The ED50 values for each agent are plotted on the x- and y- axes, respectively. Horizontal and vertical bars indicate confidence intervals.
The straight line connecting each ED50 value is the theoretical additive line and the point on this line is the theoretical additive ED50 (T). The
experimental ED50 (E) was not significantly different from T, indicating an additive interaction. Each point on the graph represents ED50 val-
ues from dose-response curves including 20-24 rats.
Fig. 4. The antagonistic effects of intrathecal naloxone (0.3 μ g) for the antinociception of intrathecal sildenafil (30 μ g) in the formalin test.
Naloxone was administered 10 min prior to the injection of formalin. Naloxone alone had little effect on the control response with formalin
(A). Naloxone reversed the effect of sildenafil during phase 1 (B) and phase 2 (C) of the formalin test. Data are presented as the percent-
age of control. Each bar represents mean±SEM of 5 rats. *, p<0.05, compared with control. 
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Naloxoneer cGMP-specific phosphodiesterase inhibitor, zaprinast, was
effective to attenuate the nociception induced by formalin
(14). Therefore, it is conceivable that the increased cGMP
level by inhibition of phosphodiesterase may contribute to
the antinociception in the spinal cord.
Phosphodiesterase enzymes occur widely in biological sys-
tems and are present in mammalian tissues (23). The cyclic
nucleotide phosphodiesterase is responsible for degrading
the second messenger nucleotides cAMP and cGMP. To date,
eleven families of PDE isoenzymes can be distinguished on
the basis of their functional characteristics, such as substrate
specificity, cellular distribution and susceptibility to selective
inhibitors (24). It has been reported that phosphodiesterases
5, 6, and 9 are specific for cGMP (5). cGMP-specific phos-
phodiesterase catalyzes the hydrolysis of cGMP to GMP. In
particular, cGMP may play a critical role in the modulation
of nociception. This proposal was based on the observation
that local injection of dibutyryl-cGMP produced antinoci-
ception in a modification of the Randall-Selitto hyperalge-
sia (3). Furthermore, local sildenafil, a phosphodiesterase 5
inhibitor, caused antinociception in carrageenan-induced
hyperalgesia, the writhing test and the second phase of the
formalin test (25-29). Additionally, intrathecal 8-bromo-
cGMP reduced mechanical allodynia in neuropathic rats (4).
These findings suggest that inhibition of this enzyme, in
turn, may increase the level of cGMP, thereby producing
antinociception. 
Intrathecal morphine reduced the flinching response in
both phases of the formalin test in the present study, corrob-
orating with previous results (11-14). Therefore, opioid recep-
tors are involved in the modulation of acute pain as well as
the facilitated state. 
The isobolographic analysis of the current study showed
an additive interaction between sildenafil and morphine in
both phases of the formalin test. These results indicate that
sildenafil cannot potentiate the antinociceptive action of
morphine itself in acute pain and the facilitated state evoked
by formalin and, vice versa. If fundamentally different mecha-
nisms jointly contribute to the observed actions of two drugs
on a given endpoint, such as antihyperalgesia, a synergistic
interaction is considered likely. However, if mechanisms of
action of one drug may be involved in those of another drug,
a synergistic interaction may not be expected. In the current
study, the antinociceptive effect of intrathecal sildenafil was
reversed by intrathecal naloxone. Furthermore, sildenafil and
morphine may have a common pharmacologic site of action,
the NO-cGMP pathway. Thus, sildenafil may not interact
with morphine in a synergistic fashion. On the other hand,
zaprinast, another phosphodiesterase inhibitor, interacted
synergistically with morphine in the spinal cord (14). More-
over, local sildenafil increased the antinociception produced
by morphine (25). Although such a difference was not fully
understood in this experiment, it could be caused by the species
of animal used, the routes and doses of the drugs adminis-
tered. In particular, sildenafil is different from zaprinast in
terms of specificity for cGMP. Sildenafil is an inhibitor of
cGMP-specific phosphodiesterase 5, but zaprinast is an in-
hibitor for phosphodiesterase 5, 6, and 9. Thus, further inhi-
bition for phosphodiesterase 6 and 9 might enhance the effect
of morphine. Another factor that might affect the drug inter-
actions is the stimulus intensity of nociception. It was pre-
viously reported that morphine interacts synergistically with
pentobarbital at a low intensity stimulus, while interacting
additively with a higher intensity stimulus (30). The extent
of antinociception produced was greater with the lower stim-
ulus intensity (31). Therefore, a synergistic relationship might
be observed with an injection of a lower formalin concentra-
tion which is believed to be a milder stimulus. An interest-
ing part of this study was the pharmacologic antagonism of
the effect of sildenafil by naloxone, which suggests that opi-
oid receptor may be affordable to the antinociceptive action
of sildenafil at the spinal level. However, it has not been
known what increased cGMP by sildenafil could exert on
opioid receptor, further research including receptor binding
study will be necessary.
Morphine is the most common opioid for the treatment
of severe pain. In particular, it can be used intrathecally for
pain control. However, side effects, including nausea and
respiratory depression, limit its use for pain control. Thus, a
combination of drugs may be recommended. The advantage
of such combination may decrease the necessary dose of each
drug, thereby increasing a maximum achievable effect with
a decreased incidence of side effects. Spinal sildenafil has not
yet been available in clinics. However, in the future it may
be used alone or in combination with morphine in the treat-
ment of pain.
In conclusion, sildenafil attenuates acute pain and the facil-
itated state evoked by formalin injection. And sildenafil inter-
acts additively with morphine. Also opioid receptor may be
involved in the antinociception of sildenafil at the spinal level.
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